nach oben

Journal of Neuro-Oncology

Erschienen in:

01.05.2015 | Laboratory Investigation

MiR-137 inhibits proliferation and angiogenesis of human glioblastoma cells by targeting EZH2

verfasst von: Jie Sun, Guodong Zheng, Zhengtao Gu, Zhenhui Guo

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

It is suggested that microRNAs play important roles in the development of various cancers. Here, we showed that miR-137 is downregulated in glioblastoma (GBM) cell lines and that low levels of miR-137 are associated with a poor prognostic phenotype of GBM patients. Ectopic expression of miR-137 significantly inhibited GBM cell proliferation and angiogenesis. In addition, ectopic expression of miR-137 inhibited tumor growth and angiogenesis in a SCID mouse xenograft model. EZH2 was identified as a direct target of miR-137 by using luciferase reporter and Western blot assays, and EZH2 overexpression can rescue the inhibitory effect of miR-137 on cell proliferation and angiogenesis. Furthermore, tumor samples from GBM patients showed an inverse relationship between miR-137 and EZH2 levels. Our results suggest that miR-137 may serve as a biomarker in GBM, and the modulation of its activity may represent a novel therapeutic strategy for the treatment of GBM patients.

Nur mit Berechtigung zugänglich

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. doi:10.1007/s00401-007-0243-4 CrossRefPubMedCentralPubMed

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiation Oncology G, National Cancer Institute of Canada Clinical Trials G (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. doi:10.1016/S1470-2045(09)70025-7 CrossRefPubMed

Plasterk RH (2006) Micro RNAs in animal development. Cell 124:877–881. doi:10.1016/j.cell.2006.02.030 CrossRefPubMed

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297CrossRefPubMed

Di Leva G, Garofalo M, Croce CM (2014) MicroRNAs in Cancer. Annu Rev Pathol 9:287–314. doi:10.1146/annurev-pathol-012513-104715 CrossRefPubMedCentralPubMed

Moller HG, Rasmussen AP, Andersen HH, Johnsen KB, Henriksen M, Duroux M (2013) A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol 47:131–144. doi:10.1007/s12035-012-8349-7 CrossRefPubMedCentralPubMed

Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG (2008) miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6:14. doi:10.1186/1741-7015-6-14 CrossRefPubMedCentralPubMed

Xie YK, Huo SF, Zhang G, Zhang F, Lian ZP, Tang XL, Jin C (2012) CDA-2 induces cell differentiation through suppressing Twist/SLUG signaling via miR-124 in glioma. J Neurooncol 110:179–186. doi:10.1007/s11060-012-0961-x CrossRefPubMed

Zhang H, Qi M, Li S, Qi T, Mei H, Huang K, Zheng L, Tong Q (2012) microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol Cancer Ther 11:1454–1466. doi:10.1158/1535-7163.MCT-12-0001 CrossRefPubMed

10.

Liu L, Wu J, Ying Z, Chen B, Han A, Liang Y, Song L, Yuan J, Li J, Li M (2010) Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion. Cancer Res 70:3750–3759. doi:10.1158/0008-5472.CAN-09-3838 CrossRefPubMed

11.

Crea F, Fornaro L, Bocci G, Sun L, Farrar WL, Falcone A, Danesi R (2012) EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev 31:753–761. doi:10.1007/s10555-012-9387-3 CrossRefPubMed

12.

Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK (2010) Regulation of tumor angiogenesis by EZH2. Cancer Cell 18:185–197. doi:10.1016/j.ccr.2010.06.016 CrossRefPubMedCentralPubMed

13.

Orzan F, Pellegatta S, Poliani PL, Pisati F, Caldera V, Menghi F, Kapetis D, Marras C, Schiffer D, Finocchiaro G (2011) Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol 37:381–394. doi:10.1111/j.1365-2990.2010.01132.x CrossRefPubMed

14.

Wu Z, Wang Q, Wang L, Li G, Liu H, Fan F, Li Z, Li Y, Tu Y (2013) Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients. J Neurol Sci 335:191–196. doi:10.1016/j.jns.2013.09.030 CrossRefPubMed

15.

Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, Yu Q (2010) Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ 17:801–810. doi:10.1038/cdd.2009.162 CrossRefPubMed

16.

Wang D, Qiu C, Zhang H, Wang J, Cui Q, Yin Y (2010) Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets. PloS One. doi:10.1371/journal.pone.0013067

17.

Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005–1017. doi:10.1016/j.cell.2009.04.021 CrossRefPubMedCentralPubMed

18.

Bader AG, Brown D, Winkler M (2010) The promise of microRNA replacement therapy. Cancer Res 70:7027–7030. doi:10.1158/0008-5472.CAN-10-2010 CrossRefPubMedCentralPubMed

19.

Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S, Xiang C, Poisson L, de Carvalho AC, Slavin S, Jacoby E, Yalon M, Toren A, Mikkelsen T, Brodie C (2013) MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget 4:665–676PubMedCentralPubMed

20.

Karsy M, Arslan E, Moy F (2012) Current Progress on Understanding MicroRNAs in Glioblastoma Multiforme. Genes Cancer 3:3–15. doi:10.1177/1947601912448068 CrossRefPubMedCentralPubMed

21.

Chen L, Wang X, Wang H, Li Y, Yan W, Han L, Zhang K, Zhang J, Wang Y, Feng Y, Pu P, Jiang T, Kang C, Jiang C (2012) miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2. Eur J Cancer 48:3104–3111. doi:10.1016/j.ejca.2012.02.007 CrossRefPubMed

22.

Sparmann A, van Lohuizen M (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6:846–856. doi:10.1038/nrc1991 CrossRefPubMed

23.

Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647:21–29. doi:10.1016/j.mrfmmm.2008.07.010 CrossRefPubMed

24.

Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman E, Niers JM, de Witt Hamer PC, Marquez VE, Cloos J, Krichevsky AM, Noske DP, Tannous BA, Wurdinger T (2010) miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 1:710–720PubMedCentralPubMed

25.

Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, Marquez VE, Clement V, Stamenkovic I (2009) EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer research 69:9211–9218. doi:10.1158/0008-5472.CAN-09-1622 CrossRefPubMed

26.

Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT (2007) EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 67:547–556. doi:10.1002/pros.20550 CrossRefPubMed

27.

Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24:268–273. doi:10.1200/JCO.2005.01.5180 CrossRefPubMed

28.

Li G, Warden C, Zou Z, Neman J, Krueger JS, Jain A, Jandial R, Chen M (2013) Altered expression of polycomb group genes in glioblastoma multiforme. PloS One 8:e80970. doi:10.1371/journal.pone.0080970 CrossRefPubMedCentralPubMed

29.

Szulwach KE, Li X, Smrt RD, Li Y, Luo Y, Lin L, Santistevan NJ, Li W, Zhao X, Jin P (2010) Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J Cell Biol 189:127–141. doi:10.1083/jcb.200908151 CrossRefPubMedCentralPubMed

30.

Bossel Ben-Moshe N, Avraham R, Kedmi M, Zeisel A, Yitzhaky A, Yarden Y, Domany E (2012) Context-specific microRNA analysis: identification of functional microRNAs and their mRNA targets. Nucleic Acids Res 40:10614–10627. doi:10.1093/nar/gks841 CrossRefPubMedCentralPubMed

31.

Li KK, Yang L, Pang JC, Chan AK, Zhou L, Mao Y, Wang Y, Lau KM, Poon WS, Shi Z, Ng HK (2013) MIR-137 suppresses growth and invasion, is downregulated in oligodendroglial tumors and targets CSE1L. Brain Pathol 23:426–439. doi:10.1111/bpa.12015 CrossRefPubMed

Titel: MiR-137 inhibits proliferation and angiogenesis of human glioblastoma cells by targeting EZH2
verfasst von: Jie Sun
Guodong Zheng
Zhengtao Gu
Zhenhui Guo
Publikationsdatum: 01.05.2015
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2015
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-015-1753-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab

Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices

Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab

Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas

Expanding schwannomatosis phenotype